Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 CIMERLI ® net sales of $52.4 million in the fourth quarter and $125.4 million in FY 2023 LOQTORZI™ and UDENYCA ONBODY™ successfully launched in Q1 2024 Reduction of work force of 30% for 2024 initiated on March 7, 2024 Conference call today at 5:00 p.m.... Read More